Probiotic bacteria such as strains of Lactobacillus acidophilus, Lactobacillus rhamnosus, and Bifidobacterium spp., and their products of fermentation, are claimed to be antimutagenic and anticarcinogenic. Exopolysaccharide (EPS) producing probiotics significantly attenuated experimental colitis, which may be mediated by the EPS in a dose-dependent manner. Therefore, EPS-producing probiotics show promise as therapeutics for the treatment of inflammatory bowel disease, and possibly in the control of cancer. In our investigations, the antimutagenic properties of acid and bile salt tolerant exopolysaccharide-producing LAB against the mutagens 4-Nitroquinoline-N-oxide (NQNO), and 2-Nitrofluorine (NF) were studied. The ability of live and dead cells of L. rhamnosus YHOC137 to bind mutagens was compared with that of L. plantarum NYC30 and Lactobacillus brevis NVC14. L. rhamnosus YHOC 137 showed 25 to 70% adsorption of both mutagens and L. brevis NVC14 showed less than 20% adsorption. Milk cultured with L. rhamnosus YHOC137 showed significant (P < 0.001) reduction of revertants in both mutagens. Fermented milk and acetone extract showed antimutagenicity levels of 29.18 to 38.91% and 8.67% to 54.46%, respectively, depending upon the tested strains. The high molecular weight neutral heteropolysaccharide had less effect against mutagenicity caused by 4NQNO but was effective against 2NF. Copyright © 2009 by New Century Health Publishers, LLC.
|Number of pages||4|
|Journal||International Journal of Probiotics and Prebiotics|
|Publication status||Published - May 2009|